Janux Therapeutics Cuts Research Spending As Quarterly Loss Falls To $21.6 Million

The drug developer holds $945.7 million in cash and short-term investments and plans to present initial autoimmune-treatment data Monday.

Share
Janux Therapeutics Cuts Research Spending As Quarterly Loss Falls To $21.6 Million

Janux Therapeutics, which develops experimental immune-system treatments for cancer and autoimmune diseases, reported a third-quarter loss of $21.6 million, versus $24.3 million a year earlier, in an SEC filing Thursday. Research spending declined as the company continued prostate cancer trials and prepared to present initial human results for its autoimmune-disease candidate Monday.

Lower Spending, Smaller Losses

Research and development costs were $30.6 million for the quarter, down from $34.6 million a year earlier. Administrative spending also fell, to $10.0 million from $10.6 million, while the per-share loss narrowed to $0.34 from $0.39.

Collaboration revenue totaled $9,289 thousand, compared with $10,000 thousand in the third quarter of 2025. For the first nine months of 2026, Janux reported a net loss of $67,903 thousand, versus $81,679 thousand in the corresponding 2025 period.

Cash, cash equivalents and short-term investments stood at $945.7 million on September 30, compared with $966.6 million at December 31, 2025. JANX shares rose about 3% to $16.59 in Friday trading.

Alongside its own drug development, Janux licenses technology and performs research with Merck and Bristol Myers Squibb. Merck funds research and has worldwide licenses for selected targets; the January 2026 agreement with Bristol Myers Squibb brought Janux a $15 million upfront payment.

Prostate Cancer Combinations Advance

Janux has dosed the first patient with JANX013 alongside JANX007 in an early-stage study for metastatic prostate cancer that resists hormone treatment. The study marks the first clinical test of its TRACIr technology, which Janux uses to develop tumor-activated immune treatments.

JANX007 testing continues in patients who have not received taxane chemotherapy. Researchers are refining doses and expanding testing, including an enrolling group receiving JANX007 with darolutamide. Janux expects additional clinical results at a medical congress in the first half of 2027.

The early-stage JANX014 prostate cancer study is also enrolling patients, evaluating safety, how the medicine behaves in the body and preliminary activity against tumors. Beyond prostate cancer, Janux's cancer pipeline includes JANX008 for multiple solid tumors.

Monday's First Autoimmune Readout

JANX011 is being tested in healthy volunteers as a potential autoimmune-disease treatment. Monday's planned presentation will provide initial human data and the first clinical evaluation of Janux's Adaptive Immune Response Modulator platform.

David Campbell, Janux's president and chief executive officer, said: “JANX011 was designed to achieve deep B-cell depletion while limiting cytokine release.” The design aims to reduce B cells while limiting the release of immune-signaling proteins.

Janux says JANX011 activates a defined subset of T cells—those expressing TRBV6—rather than broadly engaging the CD3-positive T-cell population. The company intends that selective approach to focus immune activation.

Monday's healthy-volunteer results are the next scheduled readout; Janux's additional JANX007 cancer data are expected in the first half of 2027.

Sources